Problems viewing this newsletter? View it in your browser >


New Publications on the Dual Prevention Pill and the MPT Landscape

June 8, 2023

Dear Advocate,
 
The research journal Frontiers in Reproductive Health has published a special issue on multipurpose prevention technologies (MPTs) with ten articles exploring the latest thinking on MPT development from “bench to bedside.” Among them, an article co-authored by AVAC’s Kate Segal and partners in our Dual Prevention Pill (DPP) Consortium, Equipping providers to offer novel MPTs: Developing counseling messages for the Dual Prevention Pill in clinical studies and beyond, reports on recommendations for counseling users on the DPP.
 
Another article, co-authored by CHAI and other members of the DPP Consortium, Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis, discusses the results of a modeling study that identified the conditions for the DPP to be cost effective.
 


These two articles, and the other articles in the special issue, Multipurpose Prevention Technologies for HIV, STIs & Pregnancies, provide updates on new options being tested, user preference research, strategies for product introduction, and elaborate on where the field needs to go to bring an array of new MPTs to market.
 
This comes in the midst of growing awareness that HIV, sexually transmitted infections (STIs), and reproductive health are inextricably linked. Integrating services is essential to address the pernicious effects of STIs, prevent HIV, and to offer people of childbearing age interventions that fit into their lives. MPT research and development is a central component to offering integrated services. External and internal condoms are the only MPTs currently on the market, but a growing body of evidence makes clear that people all over the world want and need choices to protect against pregnancy and other health threats, such as STIs and HIV. A variety of MPT strategies are in development now, including vaginal rings, pills, micro-array patches, injectables, implants, rectal and vaginal fast-dissolving inserts, and rectal and vaginal gels.
 
See AVAC.org’s dedicated page on MPTs to learn more, or check out our recent The Choice Agenda webinar on all things MPTs and our MPT factsheet.
 
Best,
AVAC




Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 


Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 


Contact Us T: +1 212 796 6423
E: [email protected]

W: www.avac.org